Aureus

Aureus Asset Management Appoints Thad Davis as President and Chief Executive Officer

Retrieved on: 
Tuesday, April 9, 2024

Aureus Asset Management (“Aureus” or the “Firm”), an independent investment firm dedicated to delivering long-term performance and unparalleled service to high-net-worth individuals, families, and institutional investors, today announced that Thad Davis has been appointed President and Chief Executive Officer of the Firm.

Key Points: 
  • Aureus Asset Management (“Aureus” or the “Firm”), an independent investment firm dedicated to delivering long-term performance and unparalleled service to high-net-worth individuals, families, and institutional investors, today announced that Thad Davis has been appointed President and Chief Executive Officer of the Firm.
  • Karen Firestone, Co-Founder of Aureus who previously served as Chairman and Chief Executive, has transitioned to serve as Executive Chairman.
  • Mr. Davis joined Aureus in 2005, the year the Firm was founded, as co-portfolio manager of its Core Equity Strategy.
  • Prior to joining Aureus, Mr. Davis was with Bear Stearns Asset Management where he was a vice president responsible for research and management of small and large-cap value equity portfolios.

Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil

Retrieved on: 
Tuesday, January 30, 2024

TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce ANVISA has granted commercialization approval of Ease Labs Pharma (“Ease Labs”) pharmaceutical preparation produced in Brazil containing Avicanna’s Aureus branded active pharmaceutical ingredient (“API”).

Key Points: 
  • TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce ANVISA has granted commercialization approval of Ease Labs Pharma (“Ease Labs”) pharmaceutical preparation produced in Brazil containing Avicanna’s Aureus branded active pharmaceutical ingredient (“API”).
  • Ease Labs, a GMP-certified pharmaceutical company in Brazil, was granted approval from ANVISA to commercialize a pharmaceutical preparation product containing 2.5% of CBD and up-to 0.2% THC.
  • This is the first product containing THC granted sanitary authorization under the RDC 327 and GMP certified manufacturing standards in Brazil.
  • Ease Labs expects the product to be available in pharmacies with a medical prescription by March 2024.

Nocturne Luxury Villas Invests in Exclusive 30A Rentals, a Leading Vacation Rental Management Company on Florida's Emerald Coast

Retrieved on: 
Friday, September 8, 2023

NEWPORT, R.I., Sept. 8, 2023 /PRNewswire/ -- Nocturne Luxury Villas ("Nocturne"), together with Gladstone Investment Corporation ("Gladstone Investment"), announced the completion of its investment in Exclusive 30A Rentals, LLC ("Exclusive 30A"), a leading villa rental management company operating along Florida's Scenic Highway 30A.

Key Points: 
  • NEWPORT, R.I., Sept. 8, 2023 /PRNewswire/ -- Nocturne Luxury Villas ("Nocturne"), together with Gladstone Investment Corporation ("Gladstone Investment"), announced the completion of its investment in Exclusive 30A Rentals, LLC ("Exclusive 30A"), a leading villa rental management company operating along Florida's Scenic Highway 30A.
  • Exclusive 30A complements other iconic brands already under the Nocturne umbrella, including Exceptional Stays/Telluride Rentals, St. Barth Properties, West Indies Management Company, Cabo Villas and Paradise Retreats.
  • Ms. Hamilton, Founder and CEO of the Company, commented: "Before creating Exclusive 30A, I was a homeowner and a member of the community.
  • Gladstone Investment partnered with Aureus Capital and senior management in the formation of Nocturne, a platform for acquiring and integrating luxury vacation rental management companies.

Aureus Tech Systems, a Denver-Based Developer of Cloud and AI Solutions, Celebrates Achievements of Three High School Students During Summer STEM Internship Program

Retrieved on: 
Monday, August 28, 2023

Aureus Tech Systems, Celebrates Achievements of Three High School Students During Summer STEM Internship Program.

Key Points: 
  • Aureus Tech Systems, Celebrates Achievements of Three High School Students During Summer STEM Internship Program.
  • "Aryan, Anay and Anya are prime examples of why the STEM High School Intern Program is so important.
  • All three of them worked hard on their summer break, and it was refreshing to see young minds so interested in the future.
  • Since its formation in 2008, Aureus has prioritized corporate social responsibility through inclusive internship opportunities, the Aureus Equity Scholarship, and more.

Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301

Retrieved on: 
Monday, July 17, 2023

Agreement to the proposed expansion of the confirmatory Phase 3 study in S. aureus ventilator associated pneumonia (VAP) patients to include S. aureus pneumonia in ventilated hospital acquired pneumonia (HAP) and ventilated community acquired pneumonia (CAP) patients.

Key Points: 
  • Agreement to the proposed expansion of the confirmatory Phase 3 study in S. aureus ventilator associated pneumonia (VAP) patients to include S. aureus pneumonia in ventilated hospital acquired pneumonia (HAP) and ventilated community acquired pneumonia (CAP) patients.
  • Agreement on Clinical Cure of pneumonia on Day 21 as the primary efficacy endpoint, as in the first Phase 3 study ‘AR-301-002’.
  • “We are particularly gratified to reach concurrence, first with the FDA, and now with the EMA on the overall study design, endpoints, and patient populations,” said Aridis CEO Vu Truong.
  • “This provides for a globally harmonized clinical study and regulatory pathway to bring AR-301 to patients with high vulnerabilities to Staph.

Avicanna Subsidiary SMGH Exports Aureus Branded CBD and CBG Into Paraguay

Retrieved on: 
Monday, July 17, 2023

TORONTO, July 17, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority owned subsididery Santa Marta Golden Hemp the Company has completed the commercial export of aureus branded products into Paraguay.

Key Points: 
  • TORONTO, July 17, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce that through its majority owned subsididery Santa Marta Golden Hemp the Company has completed the commercial export of aureus branded products into Paraguay.
  • The commercial export included Aureus branded purified Cannabidiol (CBD) and Cannabigerol (CBG) which is a part of the company’s portfolio of cannabinoid active pharmaceutical ingredients).
  • This transaction also marks the 17th international market for Aureus branded products and 20th market for all Avicanna products which further demonstrates the company’s capabilities in navigating complex regulatory processes for its commercialization efforts internationally.

Spectra 1000 Redefines Infection Control: Groundbreaking Disinfection System Demonstrates >99.98% Effectiveness Against Candida auris

Retrieved on: 
Tuesday, July 11, 2023

CHESTER, Conn., July 11, 2023 /PRNewswire/ -- Presenting the Spectra 1000, a pioneering disinfection system that has demonstrated exceptional effectiveness against Candida auris, a yeast pathogen causing global concern in the healthcare community.

Key Points: 
  • CHESTER, Conn., July 11, 2023 /PRNewswire/ -- Presenting the Spectra 1000, a pioneering disinfection system that has demonstrated exceptional effectiveness against Candida auris, a yeast pathogen causing global concern in the healthcare community.
  • The Spectra 1000 isn't just a new product; it redefines the paradigm of infection control.
  • Its exceptional blend of rapid room treatment times and unparalleled effectiveness is unrivaled in the industry.
  • In a world where infection control has become a top priority, the Spectra 1000 emerges as an exceptional solution for numerous facilities.

LBank Exchange Listed Aureus Nummus Gold (ANG) on June 14, 2023

Retrieved on: 
Thursday, June 15, 2023

Road Town, British Virgin Islands--(Newsfile Corp. - June 15, 2023) - LBank Exchange, a global digital asset trading platform, listed Aureus Nummus Gold (ANG) on Jun 14, 2023.

Key Points: 
  • Road Town, British Virgin Islands--(Newsfile Corp. - June 15, 2023) - LBank Exchange, a global digital asset trading platform, listed Aureus Nummus Gold (ANG) on Jun 14, 2023.
  • For all users of LBank Exchange, the ANG/USDT trading pair was officially available for trading at 9:00 UTC on Jun 14, 2023.
  • Aureus Nummus Gold (ANG) functions as a simple payments and savings tool.
  • Aureus Nummus Gold aims to create a financial system where individuals become their own bankers, controlling their assets directly from their personal vaults.

Aureus Analytics Helps The Hanover Insurance Group Extend DONNA to Select Agencies

Retrieved on: 
Tuesday, May 30, 2023

WEST HARTFORD, Conn., May 30, 2023 /PRNewswire/ -- Aureus Analytics, a global artificial intelligence technology company that provides customer experience and data analytics solutions to the insurance industry announced that The Hanover Insurance Group will offer Aureus' DONNA platform to a select number of its independent agency partners.

Key Points: 
  • WEST HARTFORD, Conn., May 30, 2023 /PRNewswire/ -- Aureus Analytics, a global artificial intelligence technology company that provides customer experience and data analytics solutions to the insurance industry announced that The Hanover Insurance Group will offer Aureus' DONNA platform to a select number of its independent agency partners.
  • DONNA is an Artificial Intelligence and Data Analytics Platform for independent agents and brokers.
  • DONNA helps independent agents to better serve their customers and enhance the value of their existing book of business.
  • The Hanover will offer DONNA to provide additional real-time data to agency partners that leverage The Hanover's Agency Insight capability.

Aureus Analytics Joins SIAA's Preferred Vendor Program with the DONNA Data Analytics Platform

Retrieved on: 
Thursday, May 18, 2023

WEST HARTFORD, Conn., May 18, 2023 /PRNewswire/ -- Aureus Analytics , a global artificial intelligence technology company that provides customer experience solutions to the insurance industry, announced that it has joined SIAA's Preferred Vendor Program.

Key Points: 
  • WEST HARTFORD, Conn., May 18, 2023 /PRNewswire/ -- Aureus Analytics , a global artificial intelligence technology company that provides customer experience solutions to the insurance industry, announced that it has joined SIAA's Preferred Vendor Program.
  • With this partnership, SIAA members will easily access Aureus' DONNA platform, enabling them to leverage cutting-edge technology to significantly transform how they manage and grow their agency.
  • "We're excited to make Aureus' DONNA platform available to SIAA members around the country.
  • DONNA is an Artificial Intelligence and Data Analytics Platform for Independent Agents & Brokers.